Cargando…

Variations in comorbidity burden in people with type 2 diabetes over disease duration: A population-based analysis of real world evidence

BACKGROUND: The prevalence of type 2 diabetes (T2DM) is increasing, but increasing longevity among persons with diagnosed diabetes may be is associated with more extensive and diverse types of morbidity. The extent and breadth of morbidity and how this varies across sub-groups is unclear and could h...

Descripción completa

Detalles Bibliográficos
Autores principales: Pearson-Stuttard, Jonathan, Holloway, Sara, Polya, Rosie, Sloan, Rebecca, Zhang, Linxuan, Gregg, Edward W., Harrison, Katy, Elvidge, Jamie, Jonsson, Pall, Porter, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356197/
https://www.ncbi.nlm.nih.gov/pubmed/35942273
http://dx.doi.org/10.1016/j.eclinm.2022.101584
_version_ 1784763464055521280
author Pearson-Stuttard, Jonathan
Holloway, Sara
Polya, Rosie
Sloan, Rebecca
Zhang, Linxuan
Gregg, Edward W.
Harrison, Katy
Elvidge, Jamie
Jonsson, Pall
Porter, Thomas
author_facet Pearson-Stuttard, Jonathan
Holloway, Sara
Polya, Rosie
Sloan, Rebecca
Zhang, Linxuan
Gregg, Edward W.
Harrison, Katy
Elvidge, Jamie
Jonsson, Pall
Porter, Thomas
author_sort Pearson-Stuttard, Jonathan
collection PubMed
description BACKGROUND: The prevalence of type 2 diabetes (T2DM) is increasing, but increasing longevity among persons with diagnosed diabetes may be is associated with more extensive and diverse types of morbidity. The extent and breadth of morbidity and how this varies across sub-groups is unclear and could have important clinical and public health implications. We aimed to estimate comorbidity profiles in people with T2DM and variations across sub-groups and over time. METHODS: We identified approximately 224,000 people with T2DM in the Discover-NOW dataset, a real-world primary care database from 2000 to 2020 covering 2.5 million people across North-West London, England, linked to hospital records. We generated a mixed prevalence and incidence study population through repeated annual cross sections, and included a broad set of 35 comorbidities covering traditional T2DM conditions, emerging T2DM conditions and other common conditions. We estimated annual age-standardised prevalence of comorbidities, over the course of the disease in people with T2DM and several sub-groups. FINDINGS: Multimorbidity (two or more chronic conditions) is common in people with T2DM and increasing, but the comorbidity profiles of people with T2DM vary substantially. Nearly 30% of T2DM patients had three or more comorbidities at diagnosis, increasing to 60% of patients ten years later. Two of the five commonest comorbidities at diagnosis were traditional T2DM conditions (hypertension (37%) and ischaemic heart disease (10%)) the other three were not (depression (15%), back pain (25%) and osteoarthritis (11%)). The prevalence of each increased during the course of the disease, with more than one in three patients having back pain and one in four having depression ten years post diagnosis. People with five or more comorbidities at diagnosis had higher prevalence of each of the 35 comorbidities. Hypertension (73%) was the commonest comorbidity at diagnosis in this group; followed by back pain (69%), depression (67%), asthma (45%) and osteoarthritis (36%). People with obesity at diagnosis had substantially different comorbidity profiles to those without, and the five commonest comorbidities were 50% more common in this group. INTERPRETATION: Preventative and clinical interventions alongside care pathways for people with T2DM should transition to reflect the diverse set of causes driving persistent morbidity. This would benefit both patients and healthcare systems alike. FUNDING: The study was funded by the National Institute for Health and Care Excellence (NICE).
format Online
Article
Text
id pubmed-9356197
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-93561972022-08-07 Variations in comorbidity burden in people with type 2 diabetes over disease duration: A population-based analysis of real world evidence Pearson-Stuttard, Jonathan Holloway, Sara Polya, Rosie Sloan, Rebecca Zhang, Linxuan Gregg, Edward W. Harrison, Katy Elvidge, Jamie Jonsson, Pall Porter, Thomas eClinicalMedicine Articles BACKGROUND: The prevalence of type 2 diabetes (T2DM) is increasing, but increasing longevity among persons with diagnosed diabetes may be is associated with more extensive and diverse types of morbidity. The extent and breadth of morbidity and how this varies across sub-groups is unclear and could have important clinical and public health implications. We aimed to estimate comorbidity profiles in people with T2DM and variations across sub-groups and over time. METHODS: We identified approximately 224,000 people with T2DM in the Discover-NOW dataset, a real-world primary care database from 2000 to 2020 covering 2.5 million people across North-West London, England, linked to hospital records. We generated a mixed prevalence and incidence study population through repeated annual cross sections, and included a broad set of 35 comorbidities covering traditional T2DM conditions, emerging T2DM conditions and other common conditions. We estimated annual age-standardised prevalence of comorbidities, over the course of the disease in people with T2DM and several sub-groups. FINDINGS: Multimorbidity (two or more chronic conditions) is common in people with T2DM and increasing, but the comorbidity profiles of people with T2DM vary substantially. Nearly 30% of T2DM patients had three or more comorbidities at diagnosis, increasing to 60% of patients ten years later. Two of the five commonest comorbidities at diagnosis were traditional T2DM conditions (hypertension (37%) and ischaemic heart disease (10%)) the other three were not (depression (15%), back pain (25%) and osteoarthritis (11%)). The prevalence of each increased during the course of the disease, with more than one in three patients having back pain and one in four having depression ten years post diagnosis. People with five or more comorbidities at diagnosis had higher prevalence of each of the 35 comorbidities. Hypertension (73%) was the commonest comorbidity at diagnosis in this group; followed by back pain (69%), depression (67%), asthma (45%) and osteoarthritis (36%). People with obesity at diagnosis had substantially different comorbidity profiles to those without, and the five commonest comorbidities were 50% more common in this group. INTERPRETATION: Preventative and clinical interventions alongside care pathways for people with T2DM should transition to reflect the diverse set of causes driving persistent morbidity. This would benefit both patients and healthcare systems alike. FUNDING: The study was funded by the National Institute for Health and Care Excellence (NICE). Elsevier 2022-08-01 /pmc/articles/PMC9356197/ /pubmed/35942273 http://dx.doi.org/10.1016/j.eclinm.2022.101584 Text en © 2022 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Articles
Pearson-Stuttard, Jonathan
Holloway, Sara
Polya, Rosie
Sloan, Rebecca
Zhang, Linxuan
Gregg, Edward W.
Harrison, Katy
Elvidge, Jamie
Jonsson, Pall
Porter, Thomas
Variations in comorbidity burden in people with type 2 diabetes over disease duration: A population-based analysis of real world evidence
title Variations in comorbidity burden in people with type 2 diabetes over disease duration: A population-based analysis of real world evidence
title_full Variations in comorbidity burden in people with type 2 diabetes over disease duration: A population-based analysis of real world evidence
title_fullStr Variations in comorbidity burden in people with type 2 diabetes over disease duration: A population-based analysis of real world evidence
title_full_unstemmed Variations in comorbidity burden in people with type 2 diabetes over disease duration: A population-based analysis of real world evidence
title_short Variations in comorbidity burden in people with type 2 diabetes over disease duration: A population-based analysis of real world evidence
title_sort variations in comorbidity burden in people with type 2 diabetes over disease duration: a population-based analysis of real world evidence
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356197/
https://www.ncbi.nlm.nih.gov/pubmed/35942273
http://dx.doi.org/10.1016/j.eclinm.2022.101584
work_keys_str_mv AT pearsonstuttardjonathan variationsincomorbidityburdeninpeoplewithtype2diabetesoverdiseasedurationapopulationbasedanalysisofrealworldevidence
AT hollowaysara variationsincomorbidityburdeninpeoplewithtype2diabetesoverdiseasedurationapopulationbasedanalysisofrealworldevidence
AT polyarosie variationsincomorbidityburdeninpeoplewithtype2diabetesoverdiseasedurationapopulationbasedanalysisofrealworldevidence
AT sloanrebecca variationsincomorbidityburdeninpeoplewithtype2diabetesoverdiseasedurationapopulationbasedanalysisofrealworldevidence
AT zhanglinxuan variationsincomorbidityburdeninpeoplewithtype2diabetesoverdiseasedurationapopulationbasedanalysisofrealworldevidence
AT greggedwardw variationsincomorbidityburdeninpeoplewithtype2diabetesoverdiseasedurationapopulationbasedanalysisofrealworldevidence
AT harrisonkaty variationsincomorbidityburdeninpeoplewithtype2diabetesoverdiseasedurationapopulationbasedanalysisofrealworldevidence
AT elvidgejamie variationsincomorbidityburdeninpeoplewithtype2diabetesoverdiseasedurationapopulationbasedanalysisofrealworldevidence
AT jonssonpall variationsincomorbidityburdeninpeoplewithtype2diabetesoverdiseasedurationapopulationbasedanalysisofrealworldevidence
AT porterthomas variationsincomorbidityburdeninpeoplewithtype2diabetesoverdiseasedurationapopulationbasedanalysisofrealworldevidence